MSTX - Mast Therapeutics, Inc.

NYSE American - NYSE American Delayed Price. Currency in USD
0.13
-0.01 (0.00%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close0.14
Open0.14
Bid0.00 x 0
Ask0.00 x 0
Day's Range0.12 - 0.14
52 Week Range0.12 - 0.14
Volume15,259,475
Avg. VolumeN/A
Market CapN/A
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Thomson Reuters StreetEventslast month

    Edited Transcript of MSTX earnings conference call or presentation 14-Mar-18 9:30pm GMT

    Q4 2017 Savara Inc Earnings Call

  • Associated Press5 months ago

    Mast reports 3Q loss

    The Austin, Texas-based company said it had a loss of 28 cents per share. Mast shares have increased 54 percent since the beginning of the year. In the final minutes of trading on Wednesday, shares hit ...

  • PR Newswirelast year

    Savara Announces Closing Of Merger With Mast Therapeutics

    AUSTIN, Texas, April 27, 2017 /PRNewswire/ -- Savara Inc. (NASDAQ:SVRA), a clinical-stage specialty pharmaceutical company focused on the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases, today announced the closing of its previously announced merger with Mast Therapeutics, Inc. (NYSE MKT: MSTX), under which the stockholders of Savara have become the majority owners of Mast, and the operations of Mast and Savara have combined. The post-merger company, named Savara Inc., is based in Austin, TX and features three inhaled product candidates, each in advanced stages of clinical development. The company will be led solely by Savara's current management team.

  • Mast Therapeutics And Savara Announce Anticipated Merger Exchange Ratio
    PR Newswirelast year

    Mast Therapeutics And Savara Announce Anticipated Merger Exchange Ratio

    SAN DIEGO, April 25, 2017 /PRNewswire/ -- Mast Therapeutics, Inc. (NYSE MKT: MSTX) and Savara Inc., a privately-held, clinical-stage specialty pharmaceutical company focused on the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases, announced today the anticipated exchange ratio calculated under the January 6, 2017 merger agreement. Upon completion of the merger, each outstanding share of Savara common stock will be automatically converted into the right to receive 0.5860 of a share of Mast common stock as adjusted for the reverse stock split being affected immediately prior to the closing of the merger (which equates to 41.0194 shares of Mast common stock before adjusting for the reverse stock split). The exchange ratio is based on each party's current capitalization and Mast's estimated net cash as of the anticipated closing date.

  • Mast Therapeutics Announces Adjournment Of Special Stockholders Meeting
    PR Newswirelast year

    Mast Therapeutics Announces Adjournment Of Special Stockholders Meeting

    SAN DIEGO, April 21, 2017 /PRNewswire/ --  Mast Therapeutics, Inc. (NYSE MKT: MSTX) today announced that the Special Meeting of Stockholders held earlier today was convened and adjourned without any business ...